Schedule 13G ownership disclosure
Contineum Therapeutics Inc
Class A Common Stock, par value $0.001 per share · CUSIP: 21217B100
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Perceptive Advisors LLC
Shares: 699,486 · Class: 3.2%
- Joseph Edelman
Shares: 699,486 · Class: 3.2%
- Perceptive Life Sciences Master Fund, Ltd.
Shares: 699,486 · Class: 3.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-108947
- Form type
- SCHEDULE 13G/A
- Filer
- Contineum Therapeutics, Inc.
- CIK
- CIK 1855175
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership